IRCT20230727058945N1 IRCT 2023-08-23 Abidi Pharmaceutical Company Empagliflozin in carotid intima-media thickness To compare the carotid intima-media thickness in ultrasound of type II diabetic patients with myocardial infarction requiring primary angioplasty in two groups receiving empagliflozin and placebo. 2023-08-13 anticipated 80 Complete https://irct.ir/trial/71820 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: Randomization method: Block randomization. By third-person coding, drug and placebo are divided into two groups, even and odd. With the random allocation rule method, a set of 40 even codes and 40 odd codes are obtained, which is recorded using the randomizer software, and based on that, the medicine is delivered to the patients. Randomization tool: Randomizer software, Blinding description: A person outside the research team labels the drug and placebo, which are both prepared by Abidi Pharmaceuticals, with labels A and B. Blocking of patients by randomizer software will be designed in 4 blocks and written on the sheets and will be chosen randomly by the patients. N/A Condition 1: myocardial infarction. Condition 2: Type 2 diabetes. Intervention 1: Intervention group: in this group, 40 type 2 diabetic patients treated with oral drugs, will recieve Empagliflozin from Abidi Pharmaceutical Company in the form of 10 mg tablets,once a day oally for 3 months. Intervention 2: Control group: in this group, 40 type 2 diabetic patients treated with oral drugs, will recieve Placbo made by Abidi Pharmaceutical Company ,once a day oally for 3 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.